Bank Of New York Mellon Corp Marker Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.24 - $4.58 $3,781 - $72,171	15,758 New	15,758 $4,000
Q4 2021 Feb 11, 2022	BUY	$0.95 - $1.72 $0 - $1	1 Added 0.01%	15,758 $15,000
Q2 2021 Aug 11, 2021	SELL	$1.88 - $3.56 $116,905 - $221,375	-62,184 Reduced 79.78%	15,757 $43,000
Q1 2021 May 13, 2021	SELL	$1.47 - $3.29 $24,895 - $55,719	-16,936 Reduced 17.85%	77,941 $174,000
Q4 2020 Feb 09, 2021	SELL	$1.36 - $1.75 $2,872 - $3,696	-2,112 Reduced 2.18%	94,877 $137,000
Q2 2020 Aug 12, 2020	BUY	$1.69 - $2.79 $24,195 - $39,944	14,317 Added 17.32%	96,989 $200,000
Q4 2019 Feb 14, 2020	SELL	$2.68 - $4.85 $1,361 - $2,463	-508 Reduced 0.61%	82,672 $238,000
Q3 2019 Nov 07, 2019	BUY	$4.1 - $9.0 $5,506 - $12,087	1,343 Added 1.64%	83,180 $425,000
Q2 2019 Aug 12, 2019	BUY	$5.15 - $7.92 $295,898 - $455,051	57,456 Added 235.66%	81,837 $648,000
Q1 2019 May 14, 2019	SELL	$5.1 - $6.71 $12,699 - $16,707	-2,490 Reduced 9.27%	24,381 $161,000
Q4 2018 Feb 11, 2019	BUY	$4.2 - $9.74 $112,858 - $261,723	26,871 New	26,871 $149,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $163M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.